XETRA · MRK.DE
Merck KGaA
€151.50+€1.20 (+0.8%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 0.39% below the high.
Loading market information…
OTC · AFMDQ · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Affimed N.V.’s quoted price sits in the lower half of its reported 52-week range, 98.35% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Affimed N.V.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.43. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Affimed N.V.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Affimed N.V. operates as a clinical-stage biopharmaceutical firm, dedicated to the discovery and advancement of immunotherapies targeting cancer across both the United States and Germany. Its primary therapeutic candidates include AFM13, which has successfully concluded Phase 2 trials for CD30-positive lymphoma, Phase 1b for Hodgkin lymphoma, and Phase 2b clinical evaluation for peripheral T-cell lymphoma. Another key candidate, AFM24, a tetravalent, bispecific innate cell engager designed to bind epidermal growth factor receptor and CD16A, is currently undergoing a Phase 2a clinical trial for patients with advanced malignancies. Additionally, AFM28, another innate cell engager (ICE), is in preclinical stages for addressing acute myeloid leukemia. Similarly, AFM32, an ICE candidate, is progressing through preclinical development for solid tumor indications. The company also maintains a collaborative partnership with Artiva Biotherapeutics, aiming to develop the combined therapy of acimtamig and AlloNK. Furthermore, a licensing and strategic alliance with Roivant Sciences Ltd. focuses on the development and commercialization of new ICE molecules, notably AFM32, within the field of oncology. A strategic collaboration with Genentech is also in place for advancing specific product candidates, encompassing novel NK cell engager-based immunotherapeutic agents designed to combat a range of cancers. Formerly named Affimed Therapeutics B.V., the entity adopted its current moniker, Affimed N.V., in October 2014. Established in 2000, its corporate headquarters are situated in Mannheim, Germany.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:00 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 |
|---|
| Mar 28, 2024 |
| -$1.35+12.34% vs estimate |
| $455.85K-72.47% vs estimate |
| Q3 2023 | Nov 14, 2023 | -$1.70-709.52% vs estimate | $2.07M+7.47% vs estimate |
|---|
| Q2 2023 | Aug 10, 2023 | -$2.20-900.0% vs estimate | $1.52M-67.42% vs estimate |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€151.50+€1.20 (+0.8%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 0.39% below the high.
$8.71-$0.16 (-1.8%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.26% below the high.
$8.50+$0.50 (+6.25%)
Eiger BioPharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
$0.03$0.00 (0.0%)
Gamida Cell Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.22% below the high.
$0.03-$0.02 (-31.78%)
Gritstone bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.98% below the high.
$0.09-$0.00 (-1.32%)
Atreca, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.5% below the high.
$0.00$0.00 (0.0%)
RVL Pharmaceuticals plc’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
$0.04-$0.01 (-13.39%)
Aravive, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.37% below the high.
